Haemonetics HAE Business Segments
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| Net revenues by Business | ||||||
| Blood Center | $221.27M-15.3% | $220.86M— | $234.64M— | $246.72M— | $261.12M— | |
| Hospital | $588.3M+4.3% | $576.51M— | $576.99M— | $569.91M— | $564.27M— | |
| Plasma | $524.46M-2.0% | $520.9M— | $516.22M— | $529.42M— | $535.43M— | |
| Operating Income by Business | ||||||
| Blood Center | $49.98M-5.4% | $48.66M— | $49.95M— | $50.93M— | $52.82M— | |
| Hospital | $103.74M+16.6% | $95.96M— | $97.42M— | $90.83M— | $88.98M— | |
| Plasma | $184.8M+0.2% | $191.74M— | $189.24M— | $191.07M— | $184.51M— | |
| Costs incurred, net of reversals by Business | ||||||
| Blood Center | -$558K-112% | -$35K-101% | -$172K-102% | $2.56M-62.2% | $4.74M-15.4% | |
| Hospital | $1.33M-20.3% | $1.49M-40.9% | $2.15M-49.4% | $1.94M-50.4% | $1.66M-56.9% | |
| Plasma | $448K— | —— | —— | —— | —— | |
| SG&A by Business | ||||||
| Blood Center | $54.13M-9.8% | $55.57M-10.3% | $56.41M-12.5% | $58.1M-12.1% | $60.02M-10.9% | |
| Hospital | $247.25M+2.3% | $242.86M+4.9% | $242.05M+7.7% | $242.89M+11.2% | $241.76M+15.3% | |
| Plasma | $105.32M+7.0% | $102.55M+1.2% | $98.99M-6.0% | $99.49M-7.4% | $98.42M-10.3% | |
| Cost of goods sold by Business | ||||||
| Blood Center | $112.67M-20.9% | $111.78M-27.5% | $122.92M-20.8% | $132.28M-17.5% | $142.51M-13.9% | |
| Hospital | $203.23M+1.9% | $203.05M+8.7% | $202.64M+12.6% | $201.03M+15.5% | $199.5M+19.3% | |
| Plasma | $214.14M-9.7% | $207.07M-19.0% | $208.92M-20.6% | $221.63M-15.8% | $237.05M-10.2% | |
| Total long-lived assets by Business | ||||||
| Blood Center | $158.88M— | $159.54M— | —— | —— | —— | |
| Hospital | $217.8M— | $211.96M— | —— | —— | —— | |
| Plasma | $812.2M— | $795.67M— | —— | —— | —— | |
| R&D by Business | ||||||
| Blood Center | $4.49M-22.1% | $4.86M-23.6% | $5.37M-21.9% | $5.41M-29.4% | $5.77M-27.5% | |
| Hospital | $34.09M+0.2% | $34.65M+8.8% | $34.87M+16.7% | $35.15M+25.3% | $34.04M+24.9% | |
| Plasma | $20.2M+30.7% | $19.55M+33.7% | $19.08M+38.6% | $17.23M+22.5% | $15.45M+12.0% | |
| Restructuring related costs by Business | ||||||
| Blood Center | -$1K-101% | $33K-86.3% | $65K-78.5% | $111K-60.9% | $154K-46.2% | |
| Hospital | $0-100% | $103K+106% | $35K-90.5% | $35K-92.5% | $143K-65.0% | |
| Plasma | $9K-96.8% | $27K-97.3% | $64K-93.8% | $115K-89.1% | $281K-73.2% | |
| D&A by Business | ||||||
| Blood Center | $7.16M-28.9% | $7.89M-27.7% | $8.62M-26.6% | $9.35M-25.6% | $10.08M-24.7% | |
| Hospital | $57.19M-0.1% | $57.2M+9.0% | $57.22M+20.0% | $57.23M+33.4% | $57.25M+50.2% | |
| Plasma | $47.37M-1.9% | $47.59M-0.1% | $47.82M+1.8% | $48.04M+3.6% | $48.26M+5.6% | |
| Currency translation by Business | ||||||
| Plasma | $0— | $0— | $0— | $0— | $0— | |
| Goodwill by Business | ||||||
| Blood Center | $108.16M-11.7% | $108.24M-16.1% | $110.01M-17.9% | $116.48M-13.0% | $122.52M— | |
| Hospital | $2.25B+2.4% | $2.2B+2.1% | $2.2B+4.6% | $2.2B+12.9% | $2.2B— | |
| Plasma | $116.17M0.0% | $116.17M0.0% | $116.17M0.0% | $116.17M0.0% | $116.17M— | |
| Total net revenues by Product | ||||||
| Plasma | $524.46M-2.0% | $520.9M-5.0% | $516.22M-8.1% | $529.42M-6.4% | $535.43M-6.0% | |
| Net revenues by Geography | ||||||
| Europe | $185.02M+5.3% | $174.4M+0.6% | $170.29M+0.6% | $169.31M+1.2% | $175.66M+9.7% | |
| Japan | $68.2M+9.3% | $65.9M+8.3% | $63.94M+8.1% | $62.35M+8.9% | $62.41M+7.4% | |
| Other | $11.42M-41.5% | $11.08M-44.9% | $14.21M-23.1% | $15.79M-4.4% | $19.54M+47.1% | |
| Rest of Asia | $87.21M-5.5% | $88.4M-9.8% | $90.97M-8.4% | $94.17M-6.2% | $92.31M-14.2% | |
| United States | $982.18M-2.8% | $978.5M-2.6% | $988.45M-0.2% | $1B+2.9% | $1.01B+4.2% | |
| Total long-lived assets by Geography | ||||||
| Europe | $112.32M— | $100.27M— | —— | —— | —— | |
| Japan | $4.38M— | $4.72M— | —— | —— | —— | |
| Other | $70.99M— | $70.61M— | —— | —— | —— | |
| Rest of Asia | $123.14M— | $121.02M— | —— | —— | —— | |
| United States | $878.04M— | $870.56M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Haemonetics break its business down?
- Haemonetics (HAE) reports net revenues by business across 3 parts — Blood Center, Hospital and Plasma. Each is extracted from the segment footnotes and tracked over time.
- Where does Haemonetics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Haemonetics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.